Page 11 - சிறப்பு ப்ரோடொகால் மதிப்பீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 29-Dec-2020 Ampio Receives feedback from the FDA on Ampio s Proposed Modifications to the special protocol assessment for Ampion treatment of severe Osteoarthritis of the knee ENGLEWOOD, Colo., Dec. 29, 2020 /PRNewswire/ Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today it has received guidance from the U.S Food & Drug Administration ( FDA ) regarding the impact of COVID-19 on its Phase III clinical trial for osteoarthritis of the knee ( OAK ). The COVID-19 health emergency has impacted clinical trials, with over 1,000 studies suspended as a result of the pandemic, including the Phase III clinical trial ( AP-013 ) for the intra-articular injection of Ampion for treatment of severe OAK. The AP-013 study is being conducted under a Special Protocol Assessment ( SPA ) which provides a

United statesSarah mayJoe hassettExchange commissionPrnewswire ampio pharmaceuticals incAmpio pharmaceuticalsUs food drug administrationCompany contactAmpio pharmaceuticals incDrug administrationSpecial protocol assessmentBiologics licensing applicationPrivate securities litigation reform actBiological license applicationAnnual reportஒன்றுபட்டது மாநிலங்களில்